张波

研究方向

1. 黄病毒和甲病毒属病毒复制包装机制：通过病毒蛋白结构和功能、病毒-宿主相互作用研究，解析黄病毒属和甲病毒属病毒的复制机制。

2. 新型疫苗的研发：以黄病毒和甲病毒为载体，研发针对新发病毒及高致病病毒的新型疫苗。

3. 抗病毒药物研究：筛选潜在的针对黄病毒和甲病毒属病毒的抗病毒药物，开展相应的抗病毒机制研究。

教育及工作经历

1994.09-1998.06，山东大学，生命科学院微生物系，学士学位；

1998.09-2001.06，山东大学，生命科学院微生物系，硕士学位；

2002.06-2005.11，德国吕贝克大学，医学分子生物学系，博士学位；

2001.07-2002.06，北京华大基因研究中心蛋白质学组，科研人员；

2006.01-2008.10，美国纽约州州立卫生署Wadsworth Center，博士后；

2008.10-2009.08，美国纽约州州立卫生署Wadsworth Center，Research Scientist I；

2009.09-至今，    中国科学院武汉病毒研究所，黄病毒学科组，研究员。

近五年承担项目

1. 国家自然科学基金联合基金：埃博拉病毒、尼帕病毒、拉沙病毒的新型载体疫苗研究，负责人，260万元，2021.01-2024.12；

2. 国家重点研发计划：病毒入侵与与复制机制，参与，70万元，2022.11-2025.12；

3. 中国科学院战略性先导科技专项：EBOV的全链条感染模型，子课题负责人，148万元，2023.01-2027.12；

4. 湖北省自然科学基金创新群体项目：重要呼吸道及虫媒病毒干预靶点的鉴定与高效、广谱药物研发，参与，8万元，2022.10-2025.09；

近五年代表性论文

1.Zhang QY^#, Zhang HQ^#, Zhang YN^#, Zhang ZR^#, Li XD, Hao MC, Zhang Y, Li JQ, Hu YY, Chen XL, Wang J, Shi YJ, Deng CL, Chen JJ, Ye HQ*, Zhang B*. Newcastle Disease Virus (NDV)-based vaccine candidate against SARS-CoV-2 Omicron by intranasal immunization. Antiviral Res. 2023 Dec;220:105757. doi: 10.1016/j.antiviral.2023.105757. Epub 2023 Nov 19.

2.Zhang HQ, Li N, Zhang ZR, Deng CL, Xia H, Ye HQ, Yuan ZM, Zhang B*. A chimeric classical insect-specific flavivirus provides complete protection against West Nile virus lethal challenge in mice. J Infect Dis. 2023 Jun 27:jiad238.

3. Li N^#, Deng CL^#, Li Q, Chen XL, Zhang B*, Ye HQ*. A safe replication-defective Zika virus vaccine protects mice from viral infection and vertical transmission. Antiviral Res. 2023 Mar;211:105549.

4. Liu J, Hu YY, Zhang QY, Zhang YN, Li N, Zhang ZR, Zhan SL, Gao L, Deng CL, Li XD, Yuan SP, He YQ,Ye HQ*, Zhang B*. Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response. Biomed Pharmacother. 2023 Feb;158:114094. doi: 10.1016/j.biopha.2022.114094.

5. Zhang HQ^#, Zhang YN^#, Zhang ZR^#, Chen XL, Hu YY, Shi YJ, Wang J, Deng CL, Zhang B*, Li XD*, Ye HQ*. An alphavirus replicon particle delivering prefusion-stabilized spike protein provides potent immunoprotection against SARS-CoV-2 Omicron variant. Signal Transduct Target Ther. 2022 Dec 14;7(1):390.

6. Zhang YN^#, Zhang ZR^#, Zhang HQ^#, Li N, Zhang QY, Li XD, Deng CL, Deng F, Shen S, Zhu B*, Zhang B*. Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters. Signal Transduct Target Ther. 2022 Feb 25;7(1):62. doi: 10.1038/s41392-022-00930-2.

7. Zhang YN, Zhang ZR, Li N, Pei XR, Li XD, Deng CL, Ye HQ*, Zhang B*. High titer self-propagating capsidless Chikungunya virus generated in Vero cells as a strategy for alphavirus vaccine development. J Virol. 2022 Mar 23;96(6):e0148021.

8. Zhang QY, Liu SQ, Li XD, Li JQ, Zhang YN, Deng CL, Zhang HL, Li XF, Fang CX, Yang FX, Zhang B*, Xu Y*, Ye HQ*. Sequence duplication in 3' UTR modulates virus replication and virulence of Japanese encephalitis virus. Emerg Microbes Infect. 2022 Dec;11(1):123-135.

9. Li JQ^#, Zhang ZR^#, Zhang HQ^#, Zhang YN^#, Zeng XY, Zhang QY, Deng CL, Li XD*, Zhang B*, Ye HQ*. Intranasal delivery of replicating mRNA encoding neutralizing antibody against SARS-CoV-2 infection in mice. Signal Transduct Target Ther. 2021 Oct 25;6(1):369.

10. Zhang YN^#, Zhang ZR^#, Zhang HQ^#, Li XD, Li JQ, Zhang QY, Liu J, Li Q, Deng CL, Shi ZL, Yuan ZM, Ye HQ*, Zhang B*. Increased morbidity of obese mice infected with mouse-adapted SARS-CoV-2. Cell Discov. 2021 Aug 25;7(1):74.

11. Zhang YN^#, Li N^#, Zhang QY^#, Liu J, Zhan SL, Gao L, Zeng XY,Yu F, Zhang HQ, Li XD, Deng CL, Shi PY, Yuan ZM, Yuan SP, Ye HQ*, Zhang B*. Rational design of West Nile virus vaccine through large replacement of 3' UTR withinternal poly(A). EMBO Mol Med. 2021 Sep 7;13(9):e14108.

12. Zhang ZR^#,Zhang YN^#, Li XD^#, Zhang HQ, Xiao SQ, Deng F, Yuan ZM, Ye HQ*, Zhang B*. A cell-based large-scale screening of natural compounds for inhibitors of SARS-CoV-2. Signal Transduct Target Ther. 2020 Oct 3;5(1):218.

13. Zhang YN^#, Li XD^#, Zhang ZR^#, Zhang HQ, Li N, Liu J, Li JQ, Zhang HJ, Wang ZJ,Shen S, Shi ZL, Wei HP, Yuan ZM, Ye HQ*, Zhang B*. A mouse model for SARS-CoV-2 infection by exogenous delivery of hACE2 using alphavirus replicon particles. Cell Res. 2020 Nov;30(11):1046-1048.

14. Ya-Nan Zhang^#, Chen Chen^#, Cheng-Lin Deng, Cheng-Guang Zhang, Na Li, Zhen Wang, Ling Zhao*, Bo Zhang*. A novel rabies vaccine based on infectious propagating particles derived from hybrid VEEV-Rabies replicon. EBioMedicine. 2020 Jun;56:102819.

15. Ya-Nan Zhang^#, Qiu-Yan Zhang^#, Xiao-Dan Li^#, Jin Xiong, Shu-Qi Xiao, Zhen Wang, Zhe-Rui Zhang, Cheng-Lin Deng, Xing-Lou Yang, Hong-Ping Wei, Zhi-Ming Yuan, Han-Qing Ye*, Bo Zhang*. Gemcitabine, Lycorine and Oxysophoridine Inhibit Novel Coronavirus (SARS-CoV-2) in Cell Culture. Emerg Microbes Infect. 2020 Dec;9(1):1170-1173. doi: 10.1080/22221751.2020.1772676.

16. Zhang QY^#, Li XF^#, Niu X, Li N, Wang HJ, Deng CL, Ye HQ, Huang XY, Chen Q, Xu YP, Dong HL, Li XD, Zhao H, Shi PY, Yuan ZM, Gong P, Fang X, Qin CF*, Zhang B*. Short direct repeats in the 3'-untranslated region are involved in subgenomic flaviviral RNA production. J Virol. 2020 Feb 28;94(6):e01175-19. doi: 10.1128/JVI.01175-19.

17. Li XD, Deng CL, Yuan ZM, Ye HQ, Zhang B*. Different Degrees of 5'-to-3' DAR Interactions Modulate Zika Virus Genome Cyclization and Host-Specific Replication.  J Virol. 2020 Mar; 94(5): e01602-19.

18. Hong-Lei Zhang^#, Hao-Long Dong^#, Ya-Nan Zhang, Lin-Lin Xu, Cheng-Lin Deng, Xiao-Feng Li, Xiao-Dan Li, Han-Qing Ye, Zhi-Ming Yuan, Cheng-Feng Qin* & Bo Zhang*. Visualization of chikungunya virus infection in vitro and in vivo. Emerg Microbes Infect. 2019;8(1):1574-1583.

19. Li N, Zhang YN, Deng CL, Shi PY, Yuan ZM, Zhang B*. Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus. J Virol. 2019 Aug 13;93(17):e00720-19. doi: 10.1128/JVI.00720-19.

20. Zhang YN^#, Deng CL^#, Li JQ, Li N, Zhang QY, Ye HQ, Yuan ZM, Zhang B*. Infectious Chikungunya Virus with a Complete Capsid Deletion: a New Approach for CHIKV Vaccine. J Virol. 2019 Jul 17;93(15):e00504-19. doi: 10.1128/JVI.00504-19.